Bayer Slashes Earnings Forecast over Rise in Roundup Cancer Cases
Bayer has slashed its earnings forecast Wednesday due to, amongst other things, a growing global legal battle surrounding the carcinogenic weedkiller Roundup. The weaker earnings forecast adds to a number of challenges facing the German drugmaker as it braces for years of legal wrangling over the cancer…